Odyssey Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
SR One Capital Management reports an 8% beneficial ownership stake in Odyssey Therapeutics following the company's IPO.
NASDAQ
TPG GP A, LLC, James G. Coulter, and Jon Winkelried have jointly filed a Schedule 13D, disclosing beneficial ownership of 3,690,146 shares, representing 7.8% of Odyssey Therapeutics, Inc.'s common stock, acquired through a concurrent private placement.
NASDAQ
Jeito II S.L.P. and associated entities have filed a Schedule 13D reporting a 7.8% beneficial ownership stake in Odyssey Therapeutics, Inc. following its recent IPO.